MariTide (maridebart cafraglutide) dosage explained: Amgen Phase 2 monthly doses of 140, 280, and 420 mg, escalation schemes, q4w vs q8w, and weight-loss results up to ~20% at 52 weeks.
PeptIQ Team
Peptide Research & Education
PeptIQ app
Log your dosing protocol in PeptIQ
Turn this guide into a living protocol — doses, vials, and history in one place.
> Note: PeptIQ is not a medical provider. MariTide (maridebart cafraglutide) is investigational. Doses below reflect published Phase 2 designs — not a consumer protocol.
MariTide is Amgen's long-acting peptide-antibody conjugate (formerly AMG 133), built for once-monthly (or less frequent) subcutaneous dosing. That monthly cadence is the SEO differentiator versus weekly tirzepatide / retatrutide calendars.
Quick Answer: MariTide Dosage
Setting
Public Phase 2 anchors
Fixed monthly doses
140 mg, 280 mg, 420 mg every 4 weeks
Less frequent arm
420 mg every 8 weeks (no escalation)
Escalation arms
Climb to 420 mg every 4 weeks over 4-week or 12-week escalation
Route
Subcutaneous
Primary readout window
Weight change at week 52
What Phase 2 Showed
In the NEJM Phase 2 program (NCT05669599):
Obesity without T2D (efficacy-style public summaries): up to about ~20% mean weight loss at 52 weeks vs ~2–3% placebo, without a clear plateau.
Obesity with T2D: up to about ~17% mean weight loss, with HbA1c reductions up to roughly 2.2 percentage points in Amgen communications.
Treatment-policy / intention-to-treat style means in the NEJM report were somewhat lower (roughly low-to-mid teens % in the obesity cohort across active arms) — always check which estimand a headline uses.
Why Escalation Exists
GI adverse events were common. Public summaries note they were less frequent with dose escalation and lower starting doses. That is the same titration philosophy as weekly incretins — just on a monthly clock.
MariTide vs Weekly Incretins (Dosing Mental Model)
MariTide
Typical weekly GLP-1 / dual / triple
Cadence
Monthly (± less frequent arms)
Weekly
Phase 2 top anchors
140–420 mg
Multi-mg weekly ladders
Design
Peptide-antibody conjugate
Peptide agonists
Adherence pitch
Fewer injections / year
Familiar weekly habit
Do not convert milligrams across products.
What to Track
Injection date (monthly calendar)
Escalation step and target maintenance dose
72-hour GI scores after each monthly shot
Protein + resistance training
Average weight, waist, labs (A1c if diabetic)
FAQ
Q: What is the MariTide dose?
A: Phase 2 studied 140, 280, and 420 mg every 4 weeks, plus 420 mg every 8 weeks and escalation schemes to 420 mg. There is no approved consumer dose.
Q: Is MariTide weekly or monthly?
A: Designed primarily as once monthly (every 4 weeks), with less-frequent arms also explored.
Q: Is MariTide the same as tirzepatide?
A: No. Different molecule, sponsor, and dosing cadence.
Bottom Line
MariTide dosing literacy starts with monthly 140 / 280 / 420 mg Phase 2 anchors, escalation for tolerability, and ~52-week weight-loss signals up to ~20% in efficacy-style summaries. Treat it as pipeline education — then track whatever your clinician actually uses.
Download PeptIQ to log monthly metabolic doses without losing the plot.
